Table 3.
List of therapeutic peptides derived by phage library screening for cancer treatment.
| Peptide sequence | Target antigen | Mechanism of action | Cancer type | Reference |
|---|---|---|---|---|
| CDCRGDCFC | Integrin | Target tumor blood vessels with doxorubicin | Human breast cancer | (57) |
| CTTHWGFTLC | MMP-2/9 | Inhibit the migration of tumor cells | Ovarian carcinoma, fibrosarcoma | (59) |
| HWWQWPSSLQLRGGGS | MMP-2 | Reduce MMP-2-mediated invasion of tumor cells | Pancreatic cancer | (60) |
| CRVYGPYLLC | MMP-9 | Inhibits proenzyme activation and cell migration | Tongue squamous cell carcinoma, fibrosarcoma | (61) |
| SMSIARL | Prostate-homing phage | Deliver a proapoptotic peptide to tumor tissue | Prostate cancer (TRAMP mice) | (62) |
| CTPSPFSHC | Vasculature of the colorectal cancer tissue | Deliver a pro-apoptotic peptide to tumor tissue | Orthotopic colorectal cancer | (63) |
| CPGPEGAGC | Aminopeptidase-P | Deliver a conjugated drug to tumor tissue | Human breast cancer | (64) |
| Cyclic RGD | MMP-2 | Antiangiogenic activity by inhibiting of MMP2 binding to αVβ3 | Human fibrosarcoma | (66) |
| ATWLPPR | VEGF | Abolish VEGF-induced angiogenesis | Rabbit corneal angiogenesis | (68) |
| WHSDMEWWYLLG | Flt-1 receptor | Reduce Flt-1-induced angiogenesis | Human breast cancer | (69) |
| CNGRCVSGCAGRC | Aminopeptidase-N | Inhibit APN-mediated angiogenesis | Human melanoma cancer | (71) |
| CGNSNPKSC | Endothelial cells of human gastric cancer | Anti-angiogenesis activity | Human gastric cancer | (74) |
| TLTYTWS | Collagen IV | Reduce endothelial differentiation and angiogenesis | Murine Lewis lung carcinoma | (75) |
| CRGDKGPDC | Neuropilin-1 | Target tumor tissue with Abraxane | Human prostate cancer | (76) |
| SVSVGMKPSPRP | Human umbilical vein endothelial cells | Target tumor tissue with doxorubicin | Human oral and lung cancer | (77) |
| CPRECESIC | Aminopeptidase-A | Suppress proliferation of endothelial cells, inhibit angiogenesis | Human breast carcinoma | (78) |
MMP, Matrix metalloproteinase-2; TRAMP, transgenic adenocarcinoma of the mouse prostate; VEGF, vascular endothelial growth factor; Flt-1, vascular endothelial growth factor receptor 1.